Expressional alterations in functional ultra-conserved non-coding rnas in response to all-trans retinoic acid - induced differentiation in neuroblastoma cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Watters, Karen M ^a,b   Bryan, Kenneth ^a,b   Foley, Niamh H ^a,b   Meehan, Maria ^a,b   Stallings, Raymond L ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

ATRA; Differentiation; neuroblastoma; Transcribed ultra conserved regions

Indexed keywords

COMPLEMENTARY RNA; RETINOIC ACID; SMALL INTERFERING RNA; UNTRANSLATED RNA;

ARTICLE; CANCER INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA STRUCTURE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; GENETIC CONSERVATION; INTRON; MICROARRAY ANALYSIS; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NEUROBLASTOMA CELL; ULTRA CONSERVED REGION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLUSTER ANALYSIS; CONSERVED SEQUENCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASM GRADING; NEUROBLASTOMA; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, UNTRANSLATED; TRANSCRIPTION, GENETIC; TRETINOIN;

EID: 84875863125     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-184     Document Type: Article

References (42)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3(3):203-216. 10.1038/nrc1014, 12612655.
2. De Preter K. Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 2006, 7(9):R84. 10.1186/gb-2006-7-9-r84, 1794547, 16989664.
3. McArdle L. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis 2004, 25(9):1599-1609. 10.1093/carcin/bgh173, 15090470.
4. Wang Q. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006, 66(12):6050-6062. 10.1158/0008-5472.CAN-05-4618, 16778177.
5. Oberthuer A. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006, 24(31):5070-5078. 10.1200/JCO.2006.06.1879, 17075126.
6. Vermeulen J. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009, 10(7):663-671. 10.1016/S1470-2045(09)70154-8, 3045079, 19515614.
7. Bray I. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 2009, 4(11):e7850. 10.1371/journal.pone.0007850, 2773120, 19924232.
8. Buckley PG. Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res 2010, 16(11):2971-2978. 10.1158/1078-0432.CCR-09-3215, 2880207, 20406844.
9. Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007, 67(3):976-983. 10.1158/0008-5472.CAN-06-3667, 17283129.
10. Mestdagh P. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010, 29(9):1394-1404. 10.1038/onc.2009.429, 19946337.
11. Schulte JH. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res 2010, 38(17):5919-5928. 10.1093/nar/gkq342, 2943620, 20466808.
12. Bejerano G. Ultraconserved elements in the human genome. Science 2004, 304(5675):1321-1325. 10.1126/science.1098119, 15131266.
13. Calin GA. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007, 12(3):215-229. 10.1016/j.ccr.2007.07.027, 17785203.
14. Mestdagh P. An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene 2010, 29(24):3583-3592. 10.1038/onc.2010.106, 20383195.
15. Scaruffi P. Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer 2009, 9:441. 10.1186/1471-2407-9-441, 2804711, 20003513.
16. Pahlman S. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ 1984, 14(2):135-144. 10.1016/0045-6039(84)90038-1, 6467378.
17. Wagner LM, Danks MK. New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem 2009, 107(1):46-57. 10.1002/jcb.22094, 19277986.
18. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985, 313(6001):404-406. 10.1038/313404a0, 3855502.
19. Das S. MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res 2010, 70(20):7874-7881. 10.1158/0008-5472.CAN-10-1534, 2955783, 20841484.
20. Bolstad BM. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19(2):185-193. 10.1093/bioinformatics/19.2.185, 12538238.
21. Irizarry RA. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264. 10.1093/biostatistics/4.2.249, 12925520.
22. Kim DY. Up-regulated hoxC4 induces CD14 expression during the differentiation of acute promyelocytic leukemia cells. Leuk Lymphoma 2005, 46(7):1061-1066. 10.1080/10428190500102589, 16019559.
23. Callen BP. Transcriptional interference between convergent promoters caused by elongation over the promoter. Mol Cell 2004, 14(5):647-656. 10.1016/j.molcel.2004.05.010, 15175159.
24. Wu K. The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. Cancer Res 2009, 69(8):3347-3355. 10.1158/0008-5472.CAN-08-3821, 2669850, 19351840.
25. Nan F. Altered expression of DACH1 and cyclin D1 in endometrial cancer. Cancer Biol Ther 2009, 8(16):1534-1539. 10.4161/cbt.8.16.8963, 19502783.
26. Harshman LA, Brophy PD. PAX2 in human kidney malformations and disease. Pediatr Nephrol 2011,
27. Liguori L. The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma. Cell Cycle 2012, 11(3):569-81. 10.4161/cc.11.3.19063, 22262177.
28. Braconi C. Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA 2011, 108(2):786-91. 10.1073/pnas.1011098108, 3021052, 21187392.
29. Sana J. Expression levels of transcribed ultraconserved regions uc.73 and uc.388 are altered in colorectal cancer. Oncology 2012, 82(2):114-8. 10.1159/000336479, 22328099.
30. Gruss P, Walther C. Pax in development. Cell 1992, 69(5):719-22. 10.1016/0092-8674(92)90281-G, 1591773.
31. Gnarra JR, Dressler GR. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by anti-sense oligonucleotides. Cancer Res 1995, 55(18):4092-8.
32. Sessa L. Noncoding RNA synthesis and loss of Polycomb group repression accompanies the colinear activation of the human HOXA cluster. RNA 2007, 13(2):223-39. 1781374, 17185360.
33. Rinn JL. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007, 129(7):1311-23. 10.1016/j.cell.2007.05.022, 2084369, 17604720.
34. Metzner A. Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D. Gene Ther 2009, 16(4):570-3. 10.1038/gt.2008.184, 19148132.
35. Yao D. Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta 2012, 413(7-8):787-94.
36. Olk-Batz C. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood 2011, 117(18):4871-80. 10.1182/blood-2010-08-298968, 21406719.
37. Caren H. Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer 2011, 11:66. 10.1186/1471-2407-11-66, 3045360, 21314941.
38. Moran A. Methylation profiling in non-small cell lung cancer: clinical implications. Int J Oncol 2012, 40(3):739-46.
39. Taniguchi H. Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene 2012, 31(15):1988-94. 10.1038/onc.2011.387, 3325596, 21892211.
40. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001, 188(2):143-60. 10.1002/jcp.1111, 11424081.
41. Humbert M. Deregulated expression of Kruppel-like factors in acute myeloid leukemia. Leuk Res 2011, 35(7):909-13. 10.1016/j.leukres.2011.03.010, 21470678.
42. Gupta RA. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464(7291):1071-6. 10.1038/nature08975, 3049919, 20393566.